Studying fibroblasts and muscle cells from persons with NS‐PME to determine the presence of glycosylation defects could provide crucial insights into the disease mechanisms and potentially redefine GOSR2‐associated disorders as part of the Congenital Disorders of Glycosylation (CDG) spectrum. The gene discussed is GOSR2; the disease is progressive myoclonus epilepsy.